IRVING, Texas--(BUSINESS WIRE)--Top oncology stakeholders from across the health care industry are set to meet this week at the MedCity CONVERGE event July 11-12 in Philadelphia. Steven Lucio, associate vice president, pharmacy services, at Vizient will be one of the featured panelists for the session, “Promising Drugs, Pricing and Access” which will focus on the impact of increasingly expensive, novel oncology therapies on the U.S. health care market. The panel will discuss potential strategies to preserve patient access to care.
The conference is an executive summit where industry thought leaders share insights on where oncology innovation is heading. It highlights best practices across the care continuum—from transformations of treatment and care delivery to patient empowerment—from some of the country’s most innovative healthcare organizations managing the disease. The event also features innovative startups in oncology be it diagnostics, therapeutics, health IT or devices from across the country.
The session Lucio will participate in, “Promising Drugs, Pricing and Access,” will be held Thursday, July 12, at 10:25 a.m. – 11:10 a.m. in the Paris Ballroom at the Sofitel Philadelphia. The event agenda notes the panel discussion will primarily focus on, “What are the solutions to continuing to foster research and innovation, while ensuring access and affordability for patients? Can biosimilars and generics expand market access in the U.S.?” The panel moderator is Bunny Ellerin, Co-Founder and President, New York City Health Business Leaders.
Panel speakers
- Patrick Davish, AVP, Global & US Pricing/Market Access, Merck
- Robert Dubois M.D., Chief Science Officer and Executive Vice President, National Pharmaceutical Council
- Gary Kurzman, M.D., Senior Vice President and Managing Director, Healthcare Safeguard Scientifics
- Steven Lucio, PharmD, BCPS, Associate Vice President, Pharmacy Services, Vizient
About Vizient, Inc.
Vizient, Inc., the largest member-driven health care performance improvement company in the country, provides innovative data-driven solutions, expertise and collaborative opportunities that lead to improved patient outcomes and lower costs. Vizient’s diverse membership base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers and represents approximately $100 billion in annual purchasing volume. The Vizient brand identity represents the integration of VHA Inc., University HealthSystem Consortium and Novation, which combined in 2015, as well as MedAssets’ Spend and Clinical Resource Management (SCM) segment, including Sg2, which was acquired in 2016. In 2018, Vizient again received a World’s Most Ethical Company designation from the Ethisphere Institute. Vizient’s headquarters are in Irving, Texas, with locations in Chicago and other cities across the United States. Please visit www.vizientinc.com as well as our newsroom, blog, Twitter, LinkedIn and YouTube pages for more information about the company.
